21 September 2011 (Wednesday) - JAK-2
Here’s a thought… There is an awful lot of overlap in various clinical and morphological features seen in myeloproliferative disorders. And for some time JAK-2 mutation screening has been becoming more and more of a popular test in the diagnosis, even though it’s not diagnostic. (About 50% of essential thrombocythaemia patients test positive for the JAK2 mutation whereas about 97% of polycythemia rubra vera patients).
There’s now a school of thought that suggests myeloproliferative disorders should be re-classified as JAK-2 positive of JAK-2 negative myeloproliferative disorder. I don’t really know that much about JAK-2: I shall have to find out more…
Labels: journal review